Technical Analysis for CRY - CryoLife, Inc.
CRY closed up 2.62 percent on Friday, November 21, 2014, on 1.78 times normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. It ran into resistance at its 50 day moving average.
|Rating||Last Price||% Change||$ Change||Track This Stock|
|$9.81||2.62%||0.25||+ Watchlist + Portfolio|
|See historical CRY trend table...|
|2014-11-21||Upside 200 DMA Break||Bullish|
|2014-11-21||50 DMA Resistance||Bearish|
|2014-11-20||Stochastic Buy Signal||Bullish|
|2014-11-17||200 DMA Resistance||Bearish|
|2014-11-17||Stochastic Reached Oversold||Other|
|2014-11-14||Downside 200 DMA Break||Bearish|
|2014-11-12||200 DMA Support||Bullish|
Is CRY a Buy, Sell or Hold?:
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought||X|
|Relative Strength||X||Summary:||Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. More to come...|
Sector: Health Care
Industry: Medical/Dental Instruments
CryoLife, Inc. preserves and distributes human tissues for transplantation in the United States and internationally. The company also develops, manufactures, and commercializes medical devices for cardiac and vascular applications. It distributes CryoValve SG pulmonary heart valves and CryoPatch SG pulmonary cardiac patch tissues that are processed using CryoLifes proprietary SynerGraft technology; and vascular tissues comprising CryoVein and CryoArtery to treat various vascular reconstructions, such as peripheral bypass, hemodialysis access, and aortic infections. The company also distributes surgical sealants and hemostats, including BioGlue Surgical Adhesive, an adjunct to sutures and staples for use in adult patients in open surgical repair of vessels, as well as in repair of cardiac, vascular, pulmonary, and additional soft tissues. In addition, its surgical sealants and hemostats comprise BioFoam Surgical Matrix for use as an adjunct in the sealing of abdominal parenchymal tissues, when cessation of bleeding by ligature or conventional methods is ineffective or impractical; PerClot, an absorbable powdered hemostat agent used in surgery; and revascularization technologies, which include transmyocardial revascularization system for treating patients with stable angina that is not responsive to conventional therapy. CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of coronary artery disease for severe angina using a laser console system and single use, fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization. The company, through its subsidiary, Hemosphere, Inc., markets HeRO Graft, a solution for end-stage renal disease in certain hemodialysis patients. CryoLife distributes its products through field service representatives, cardiac specialists, direct field representatives, and independent distributors. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
Recent news:See more CRY news...
Average Volume: 109,482
Average True Range: 0.33
Chandelier Exit (Long): 9.82
Chandelier Exit (Short): 10.16
52 Week High: 12.14
52 Week Low: 8.4
200-Day Moving Average: 9.69
50-Day Moving Average: 10.15
20-Day Moving Average: 9.97
10-Day Moving Average: 9.7
Upper Bollinger Band: 10.68
Lower Bollinger Band: 9.26
Percent B (%b): 0.39